MedTrace Logo

A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.

NCT02185040 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2020-03-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether CC-220 is effective for the treatment of skin, joint and serological manifestations of systemic lupus erythematosus.

Conditions

Interventions

DRUG

CC-220

0.3 mg oral capsules once every other day with or without food

DRUG

CC-220

Subjects will receive 0.3 mg oral capsules every day with or without food

DRUG

CC-220

CC-220 oral capsules 0.6 mg and 0.3 mg on alternating days with or without food

DRUG

CC-220

CC-220 oral capsule 0.6 mg QD with or without food

DRUG

Placebo

Matching oral placebo daily

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Shimon Korish, M.D. · Celgene

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-16
Primary Completion
2018-09-25
Completion
2018-09-25

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02185040 on ClinicalTrials.gov